

# Our Position on Science

## We believe...

**emerging science and new technologies are creating new opportunities** to transform the practice of medicine.

- A deep knowledge of the biology of disease pathways in immunology and monogenic disorders will lead to the development of new treatments that make a meaningful difference in the lives of patients.
- Translating scientific knowledge into cutting-edge therapies that change the practice of medicine requires new platforms such as those based on Nanobodies®, mRNA, gene therapy or synthetic biology.
- An understanding of patient experience is critical to pioneering innovation, as is the development of outstanding digital R&D capabilities.
- Biopharmaceutical science has significant potential to create economic value and highly skilled jobs and to be a leading driver in building the economy of this century.

## We offer...

**a combination of cutting-edge technologies and expertise** that fuel our robust pipeline.

- Thanks to our science millions of people have the possibility to access our medicines and vaccines every year (*e.g., 500 million people vaccinated annually*).
- Our unique disease insights stand out in human immunology (*vaccines, multiple sclerosis, immunoncology, immunology & inflammation*) and monogenic disorders (*rare genetic diseases, hemophilia*).
- Our strategic decisions are advancing our scientific progress by improving efficiency, accelerating the pace of our decision making and making strategic acquisitions (*Ablynx, Synthorx, Kiadis and Principia*) that give us access to next generation therapeutic platforms.
- We are transforming our R&D engine; with a strong increase of Sanofi's assets in development (75%) with the potential to be the best therapeutic solution for patients in our prioritized therapeutic areas. Likewise, approximately 65% of Sanofi's drug candidates come from in-house research and development.
- We are enhancing speed and efficiency of our drug discovery efforts by integrating digital technologies and approaches such as artificial intelligence, machine learning and real-world evidence.

## We ask...

for fair recognition of our efforts to transform the practice of medicine.

- Governments to protect intellectual property rights to accelerate and create a receptive environment for scientific breakthroughs.
- Governments to adopt policies that encourage and boost the biopharma ecosystem and reward innovation that has the potential to make a meaningful difference in therapeutic areas with significant patient needs.
- Governments to promote sustainable dialogue with the private sector and implement public-private-partnership initiatives to accelerate translation of valuable scientific

